Article
The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia.
Molecular biomedicine - 4 Sept 2026
Wang Shiyang, Zhang Yvyin, Zhong Zhiwei, He Jiajun, Fan Jiaqi, Xiang Qi, Yang Fangfang, Zhang Yuping, Wang Shunqing, Wang Peihong
Abstract excerpt
FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (FLT3-ITD) is a well-characterized genetic alteration associated with poor prognosis in acute myeloid leukemia (AML). Although FLT3 inhibitors, such as gilteritinib and quizartinib, initially show clinical efficacy, resistance frequently emerges because of secondary mutations. Through a kinase inhibitor library screen, we identified XL999, which...
Read the complete abstract on PubMedTopics
- fms-Like Tyrosine Kinase 3
- Leukemia, Myeloid, Acute
- Animals
- Humans
- Benzothiazoles
- Phenylurea Compounds